EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON THERAPEUTICS PLC AND HORIZON THERAPEUTICS USA, INC. AND AARON L. COXEmployment Agreement • August 3rd, 2022 • Horizon Therapeutics Public LTD Co • Pharmaceutical preparations • Illinois
This Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Therapeutics PLC., an Irish Public Limited Company, and its wholly owned subsidiary, Horizon Therapeutics USA, Inc., a Delaware corporation, having a principal place of business at 1 Horizon Way, Deerfield IL 60015, (hereinafter referred to together as the “Company”) and Aaron L. Cox (hereinafter referred as to the “Executive”). The terms of this Agreement shall be effective commencing November 1, 2021 (the “Effective Date”).
AMENDMENT NO. 4 TO COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • August 3rd, 2022 • Horizon Therapeutics Public LTD Co • Pharmaceutical preparations
This Amendment No. 4 (the “Amendment” or this “Amendment No. 4”) to the Commercial Supply Agreement by and between Horizon Therapeutics Ireland DAC, formerly known as Horizon Pharma Ireland Limited (“Customer”) and AGC Biologics A/S, formerly known as CMC Biologics A/S (“AGC”) is dated as of May 31, 2022 (“Amendment Effective Date”).
EXECUTIVE EMPLOYMENT AND TRANSITION AGREEMENTEmployment and Transition Agreement • August 3rd, 2022 • Horizon Therapeutics Public LTD Co • Pharmaceutical preparations • Illinois
This Executive Employment and Transition Agreement (this “Agreement”) is entered into on May 11, 2022, by and among Horizon Therapeutics plc, an Irish Public Limited Company, and its wholly owned subsidiary, Horizon Therapeutics USA, Inc., a Delaware corporation, having a principal place of business at 1 Horizon Way, Deerfield, Illinois 60015 (hereinafter referred to together as the “Company”) and Paul W. Hoelscher (the “Executive”), and replaces and supersedes that certain Executive Employment Agreement dated June 17, 2014 and that certain First Amendment to Executive Employment Agreement dated May 4, 2017 (collectively the “Prior Agreements”), by and between Horizon Therapeutics USA, Inc. and the Executive. This Agreement shall become effective on the “Effective Date” specified in Section 10 below.
